Clinical Trial Update: A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 extension study evaluating Revusiran (ALN-TTRSC) in transthyretin cardiac amyloidosis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-related Cardiac Amyloidosis
• Ttr-mediated Amyloidosis

Drugs mentioned

• Revusiran (ALN-TTRSC)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: TTR-mediated Amyloidosis | Phase 2 | Status: COMPLETED | Results posted: 2018-06-15